Jane Street Group LLC Sells 42,478 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Jane Street Group LLC trimmed its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 21.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 157,619 shares of the company's stock after selling 42,478 shares during the quarter. Jane Street Group LLC owned 0.22% of Nurix Therapeutics worth $3,542,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of NRIX. Amalgamated Bank grew its stake in shares of Nurix Therapeutics by 30.6% in the third quarter. Amalgamated Bank now owns 2,182 shares of the company's stock valued at $49,000 after buying an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Nurix Therapeutics by 31.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock worth $54,000 after purchasing an additional 559 shares during the period. Quest Partners LLC lifted its position in shares of Nurix Therapeutics by 21.3% during the third quarter. Quest Partners LLC now owns 7,458 shares of the company's stock worth $168,000 after purchasing an additional 1,312 shares in the last quarter. ClariVest Asset Management LLC boosted its stake in shares of Nurix Therapeutics by 2.9% in the second quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company's stock valued at $1,318,000 after purchasing an additional 1,766 shares during the period. Finally, Quarry LP grew its stake in shares of Nurix Therapeutics by 3,746.2% in the third quarter. Quarry LP now owns 2,500 shares of the company's stock worth $56,000 after acquiring an additional 2,435 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on NRIX. Jefferies Financial Group started coverage on Nurix Therapeutics in a report on Friday, October 11th. They issued a "buy" rating and a $41.00 target price for the company. Stephens reiterated an "overweight" rating and issued a $31.00 price target on shares of Nurix Therapeutics in a research note on Monday, October 14th. Robert W. Baird assumed coverage on Nurix Therapeutics in a report on Friday, September 6th. They set an "outperform" rating and a $26.00 price target for the company. UBS Group initiated coverage on shares of Nurix Therapeutics in a research note on Thursday, October 24th. They issued a "buy" rating and a $35.00 price objective for the company. Finally, BTIG Research began coverage on Nurix Therapeutics in a research note on Tuesday, December 10th. They issued a "buy" rating and a $35.00 price objective for the company. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $30.35.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX traded down $0.21 during trading hours on Friday, hitting $19.83. 2,913,842 shares of the stock were exchanged, compared to its average volume of 912,122. The firm has a market capitalization of $1.40 billion, a P/E ratio of -6.81 and a beta of 2.11. The company's 50 day moving average is $23.46 and its 200 day moving average is $22.29. Nurix Therapeutics, Inc. has a one year low of $7.65 and a one year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67). Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. The business had revenue of $12.59 million during the quarter, compared to analysts' expectations of $13.85 million. Research analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current fiscal year.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 2,368 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $57,542.40. Following the completion of the transaction, the chief financial officer now directly owns 37,270 shares in the company, valued at $905,661. This represents a 5.97 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Christine Ring sold 5,760 shares of the company's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $22.23, for a total value of $128,044.80. Following the sale, the insider now owns 24,592 shares in the company, valued at $546,680.16. The trade was a 18.98 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,401 shares of company stock worth $437,453. Corporate insiders own 7.20% of the company's stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.